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Abstract 
 
Purpose: Recently, several studies have investigated genetic associations between 
Cytochrome P450 (CYP1B1), Endothelial nitric oxide synthase (eNOS) and 
Neurotrophin-4 (NTF4) with primary angle-closure glaucoma (PACG) in various 
ethnic groups. Here we investigate the association of these candidate genes with 
PACG in samples from Australia and Nepal. 
 
Method: A total of 235 patients with PACG (106 Nepalese and 129 Australian) and 
492 controls (204 Nepalese and 288 Australian) were included. Tag single nucleotide 
polymorphisms (SNPs) were selected to cover the majority of common variation 
within the candidate genes and genotyped in DNA extracted from peripheral whole 
blood. Allele and haplotype analyses were conducted in PLINK. Bonferroni 
correction was applied for the total number of SNPs in this study (p=0.05/15=0.003) 
 
Results: In the Australian cohort, one eNOS SNP rs3793342 shows significance 
association with PACG in the Australian cohort after Bonferroni correction (p-value 
0.003, OR 0.5 95% CI 0.3-0.8). After adjusting the results for sex and age both SNPs 
rs3793342 and rs7830 showed significance after Bonferroni correction (p-value of 
0.001 and 0.003, respectively). The eNOS haplotype of all 7 typed SNPs showed 
significant association with a global p-value of 0.019, with the CGCAATC haplotype 
giving a specific p-value of 0.008 and odds ratio of 1.5 (95% CI 0.9-2.4). In the 
Nepalese cohort, SNPs in CYP1B1 and NTF4 genes showed borderline association 
with PACG but did not survive Bonferroni correction.  
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Conclusions: The present data support the involvement of common variations 
in eNOS with PACG pathogenesis. Differences were observed in the two populations 
studied, and additional replication studies in other populations are necessary to 
confirm these associations 
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Introduction 
Glaucoma is the leading cause of irreversible blindness worldwide [1] with primary 
open angle glaucoma (POAG) being the most prevalent subtype. However primary 
angle-closure glaucoma (PACG) is responsible for almost half of all glaucoma 
blindness. [2] Family history and ethnicity are important risk factors for PACG. The 
disease is more prevalent amongst Asians and Eskimos than in Caucasians and 
Africans. [3] In addition, first degree relatives of patients with PACG have a higher 
probability of developing narrow angles. [4, 5] The number of patients with PACG 
worldwide is expected to rise from around 16 million in 2010 to 21 million by the 
year 2020 [6] with the majority of bilaterally blind PACG patients expected to be of 
Asian ethnicity. [7] 
Patients with PACG share certain anatomical biometric features including short 
anterior chamber depth with narrowing in the irido-corneal drainage angle, increased 
lens thickness and anterior apposition of the lens, short axial length and hyperopic 
(farsightedness) refractive error. [8]  
The leading cause of PACG is from obstruction of the trabecular meshwork, which 
leads to the accumulation of aqueous humor and subsequent increase in intraocular 
pressure. This in turn causes progressive destruction of the optic nerve with 
corresponding loss of the peripheral visual field. [6]  
 
PACG is a complex heterogeneous disease. Recently Vithana and colleagues 
conducted a large two-staged genome-wide association study and reported three 
susceptibility loci: rs11024102 in PLEKHA7; rs3753841 in COL11A1, and rs1015213 
located between PCMTD1 and ST18. [9] Prior to this, evaluation of PACG genetics 
Archived at the Flinders Academic Commons: http://dspace.flinders.edu.au/dspace/ 
5 
 
has been conducted through evaluation of candidate genes chosen for biological 
plausibility or association with similar phenotypes. Several genes have previously 
been reported to be associated with other subtypes of glaucoma. For example 
Cytochrome P450 (CYP1B1) is well known to cause primary congenital glaucoma 
(PCG), [10, 11] while Endothelial nitric oxidase synthase (eNOS) [12, 13] and 
Neurotrophin-4 (NTF4) have been implicated in primary open angle glaucoma 
(POAG). [14] As all three types of glaucoma (POAG, PCG and PACG) are 
characterised by destruction of the optic nerve and progressive increase in the 
cup:disc ratio, generally with elevated intraocular pressure, we hypothesised that 
variations within these POAG and PCG genes may also be associated with PACG. 
 
CYP1B1 is the most common gene known to be involved with the pathogenesis of 
PCG. [15, 16] It accounts for around 20% of PCG cases in Australia. [17] Sarfarazi 
and colleagues [10] hypothesized that CYP1B1 [OMIM 601771] is involved in the 
development of the anterior chamber angle of the eye, making it a gene of interest for 
PACG. Chakrabarti and colleagues [18] sequenced the coding region of the gene and 
found association of mutations with PACG in an Indian cohort consisting of 90 cases 
and 200 controls. A smaller study of 29 PACG patients from the Middle East did not 
report any known or novel polymorphisms in CYP1B1, using direct sequencing. [19]  
 
Nitric oxide (NO) is synthesized in the vascular endothelium by endothelial nitric 
oxide synthase 3 (also known as eNOS), from the substrate L-arginine. [20] eNOS 
[OMIM 163729] over expression is thought to be neuroprotective by causing 
vasodilation and increased blood flow in human eye tissues. [21] Overexpression of 
eNOS was also reported to lower intraocular pressure in the mouse eye by increasing 
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the pressure dependent drainage. [22] Other factors such as asymmetric 
dimethylarginine (ADMA) and symmetric dimethylarginine (SDMA) play an 
inhibitory role in the production of NO. Our laboratory found that serum levels of 
both ADMA and SDMA are significantly elevated in patients with advanced POAG 
suggesting dysregulation of the NO system in this disease. [23]  
 
Furthermore NO enhances the activity of Matrix metalloprotinase-9 (MMP9) [24] 
which has also been reported to be associated with PACG. [25, 26] Alteration in 
MMP9 activity during eye development may lead to hyperopic refractive error which 
is a risk factor for PACG. [26, 27] It has been proposed that alteration of eNOS 
expression causes impairment of blood flow and subsequent development of angle-
closure. The 27-bp variable number of tandem repeat (VNTR) polymorphism in 
intron 4 of eNOS is believed to alter the production of nitric oxide and cause vascular 
deregulation. [28] This variation was found to be associated with PACG in Pakistani 
cohorts. [29] A study of Han Chinese used tag SNPs to identify association of 
common variants in the eNOS gene in 88 patients with PACG, but no associations 
were observed. [30]  
 
Heterozygous mutations in NTF4 [OMIM 162662] were recently reported to be 
responsible for 1.7% of POAG cases of European descent. [14] Neurotrophin plays a 
vital role in the neuronal cell development, survival and differentiation and it was 
suggested that the pathway may also prevent neuronal damage in retinal ganglion 
cells. [14] Two studies have looked for association with PACG in Indian [31] and 
Caucasian European [32] populations respectively by sequencing the coding exons, 
but failed to detect association.  
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Thus, although these three genes are plausible candidates, results are inconsistent 
between published studies and even less so across ethnicities. Thus, in this study, we 
aimed to investigate the association between tag SNPs in these three genes and 
PACG in both Australian and Nepalese cohorts in order to determine if common 
variation in these genes could contribute to disease in these populations. 
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Methods 
Australian Caucasian participants were recruited from Ophthalmology clinics in 
Australia through the Australian and New Zealand Registry of Advanced Glaucoma. 
[33] Approval was obtained from the human research ethics committee of the 
Southern Adelaide Health Service and Flinders University. All participants were self-
reported Caucasian. The Nepalese cohort was recruited from the Nepal Glaucoma 
Eye Clinic, Tilganga Institute of Ophthalmology, Kathmandu Nepal by one of the 
authors (S.S.T). The study was approved by the Institutional Review Committee of 
the Tilganga Institute of Ophthalmology (TIO). All participants were from Nepal and 
detailed ethnic group information was collected. [34, 35] This study has been 
conducted in accordance with the Declaration of Helsinki and its subsequent 
revisions. Informed consent was obtained from each individual.  
Following the International Society of Geographical and Epidemiological 
Ophthalmology (ISGEO) [36] diagnosis of PACG was based on the presence of 
glaucomatous optic neuropathy with cup:disc ratio≥ 0.7, intraocular pressure more 
than 21 mmHg, peripheral visual loss, presence of at least 180 degrees of closed 
angle in which the trabecular meshwork is not visible on gonioscopy. In this study 
129 Australian and 106 Nepalese affected participants were recruited, they were all 
identified with PACG.  
Controls were required to have none of the above characteristics, with no known 
family history of glaucoma. Participants with pseudophakia or secondary angle-
closure glaucoma caused by events such as uveitis, trauma or lens subluxation were 
excluded. The control groups consisted of 288 Australian and 204 Nepalese 
individuals. The Australian control cohort was ascertained from nursing home 
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facilities in Adelaide, South Australia. Nepalese controls were participants in a 
population based study of Kathmandu, Nepal, in which the individuals were chosen 
specifically to be matched for age, gender and ethnic group to the Nepalese cases 
[34]. Each participant underwent a complete eye examination including; slit lamp 
examination of the anterior chamber, gonioscopy, best corrected visual acuity, 
measurement of intraocular pressure, fundus examination with special attention to 
optic disc parameters, and visual field assessment. Refraction was carried out using a 
streak retinoscope (Beta 200, Heine, Germany), which was followed by a subjective 
refraction [34].  
 
Genomic DNA was extracted from peripheral whole blood using the QiaAmp Blood 
Midi (Nepalese samples) or Maxi (Australian samples) Kit (Qiagen, Valencia, 
California).  
15 Tag SNPs were selected using the tagger program implemented in Haploview 4.2 
(http://www.broadinstitute.org/scientific-community/science/programs/medical-and-
populationgenetics/haploview/haploview) to cover the majority of known genetic 
variation in and around the candidate genes (CYP1B1 5 SNPs, eNOS 7 SNPs, and 
NTF4 3 SNPs). For the Nepalese cohort, SNPs were selected from the HapMap 
(http://hapmap.ncbi.nlm.nih.gov/) Han Chinese in Beijing, China (CHB) sample as 
the most closely related population available at the time of the study. For SNP 
selection in the Australian cohort we used CEU: CEPH (Utah residents with ancestry 
from northern and western Europe). Tag SNPs were chosen using pairwise tagging, 
to have an r
2
>0.8 with SNPs displaying a minor allele frequency of >5% in the 
relevant HapMap II population.  
Genotyping was conducted using the iPLEX Gold chemistry (Sequenom Inc, San 
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Diego, California) on an Autoflex mass spectrometer (Sequenom Inc, San Diego, 
California) at the Australian Genome Research Facility (AGRF), Brisbane. All 
analyses were conducted using PLINK. [37] SNPs were assessed for compliance 
with Hardy-Weinberg equilibrium using the χ2 test. Genetic association was assessed 
under an allelic model. Analysis is with respect to minor allele of the tag SNPs. P-
values were adjusted for sex and age using logistic regression. A Bonferroni 
correction was applied to each p-value according to the number of SNPs typed in this 
study (corrected p-value; 0.05/15= 0.0033). Haplotype analyses were conducted in 
PLINK based on the observed linkage disequilibrium blocks, as visualised using the 
“solid spine” definition in Haploview. [38]  
We further analysed the association between eNOS and MMP9 with PACG in the 
Australian cohort by comparing the combined risk alleles with the protective one 
using chi-square test. The data for MMP9 was that previously published on a subset 
of the Australian cohort. [25] We selected the significant SNP from each gene eNOS 
rs3793342 and MMP9 rs17576. 
The power of this study at α=0.05 was assessed using the Genetic Power Calculator. 
[39] The prevalence is similar in both Australian 0.4% [40] and Nepalese cohorts 
0.43%. [41] Assuming complete linkage disequilibrium between the disease causing 
variant and the marker we will have a power of 89% to detect a genotypic relative 
risk of 1.3 with a risk allele frequency of 0.2 under an additive model. 
 
Results 
417 Australian and 310 Nepalese participants were enrolled in this study. All cases in 
the Nepalese cohort presented with PACG, of which 53 cases were reported to have 
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had an acute attack. In the Australian cohort 129 cases were identified with PACG 
(35 with previous history of acute attack). Table 1 displays the demographic 
characteristics and clinical data of the cases and controls for each cohort. No SNP 
deviated from Hardy-Weinberg equilibrium in either cohort (p>0.05). The physical 
locations of the tag SNPs are presented in Figure 1. 
 
The minor allele frequencies and allelic association p-values of typed SNPs in the 
Australian cohort are presented in Table 2. Three SNPs in eNOS were found to show 
significant association with PACG; rs3793342, T allele, with p-value of 0.003 (OR 
0.5, 95%CI 0.3-0.8), rs3918188, A allele, with p-value of 0.014 (OR1.5, 95%CI 1.1-
1.9), and rs7830, A allele, p-value=0.007 (OR 0.7, 95%CI 0.5-1.0). Only rs3793342 
survived correction for multiple testing of 15 SNP (p-value 0.001). However, after 
justifying the Australian cohort for age and sex, both rs3793342 and rs7830 were 
significant with p-value of 0.001 and 0.003, respectively. One haplotype in the eNOS 
gene also showed association with PACG in the Australian cohort, with a global p 
value of 0.019. The CGCAATC haplotype conferred risk, with significant p-value of 
0.009 (OR 1.5, 95%CI 0.9-2.4). This haplotype contains the risk alleles of all the 
three nominally associated SNPs (Table 3).  
When we further analysed the association between eNOS and MMP-9 with PACG in the 
Australian cohort, a significant difference in the rate of PACG was found between 
individuals carrying the risk alleles of both SNPs rs17576 in MMP-9 and rs3793342 in 
eNOS (105 individuals) with those who do carry the protective allele only (264 
individuals) with p-value 0.048 (OR 2.8).  
No statistically significant association was observed across the CYP1B1 or NTF4 
loci. 
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The allele frequencies and association p-values of typed SNPs in the Nepalese cohort 
are presented in Table 4. Two SNP from the CYP1B1 gene were nominally 
significant; rs10916, G allele, with odds ratio 2.1 (95%CI 1.1-4.0, p=0.02), and 
rs162561, A allele, with odds ratio 2.2 (95% CI 1.1-4.3, p=0.01). Both SNPs 
remained significant after adjustment for sex and age, however did not survive 
Bonferroni correction. Similarly in the NTF4 gene one SNP, rs11669977 T allele, 
showed p-value of 0.04 with odds ratio of 1.5 (95% CI 1.0-2.4) but did not survive 
correction for the 15 SNPs typed. No significant associations were identified with 
eNOS in this cohort.  
In the Nepalese cohort, the global p-value for the haplotypes of all five SNP markers 
tested in CYP1B1 gene was not significant (0.11). However, one haplotype, AGCAC, 
showed a nominally significant association with PACG with p-value of 0.02 (odds 
ratio 2.2, 95% CI 0.7-6.7) (Table 5), but did not survive correction for multiple 
testing of five haplotypes (corrected p-value 0.1). The remaining genes did not show 
any significant haplotypic association in this cohort (data not shown).  
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Discussion 
Primary angle-closure glaucoma is a complex disease, believed to arise from 
interactions between genetic variants and environmental effects. Here we chose three 
genes targeting different function in the pathogenesis of glaucoma; development of 
anterior chamber (CYP1B1), retinal ganglion cell development and survival (NTF4), 
and regulation of intraocular pressure (eNOS). All three genes have previously been 
implicated in POAG or PCG, and have been proposed as likely candidates for 
PACG.  
 
CYP1B1 is well known for its association with primary congenital glaucoma (PCG). 
[11, 42, 43] It is expressed in tissues of the anterior chamber of the eye such as 
ciliary body, iris and trabecular meshwork. [29, 30] CYP1B1 was hypothesized to 
take part in the normal development and function of the eye and is involved in the 
development of the anterior chamber angle. [10] Association was found with PACG 
in an Indian population [30], but not in a Middle Eastern cohort using sequencing 
methodology. [19] Here we genotyped tag SNPs to look for common variations in 
and around the gene. Our study shows nominal association in the Nepalese cohort 
under both single SNP and haplotypic analyses, however this association was not 
considered significant given the number of tests conducted. Thus, a larger cohort will 
be required to confirm this putative association. 
  
When ocular tissues are subjected to stress, nitric oxide (NO) is released from the 
ocular vascular endothelium causing an increase in the ocular blood flow and oxygen 
delivery to the retina. [44] NO is produced from the endothelial nitric oxide synthase 
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(eNOS or NOS3) enzyme. NO synthesis sites are abundantly located in the ciliary 
muscle and the outflow pathway of normal human eye. It has been hypothesized to 
be involved in IOP regulation, either directly through affecting the outflow resistance 
at the level of the trabecular meshwork, or indirectly through affecting the tone of the 
ciliary muscle. [45] In addition to a role in IOP modulation, eNOS also affects the 
blood flow to the optic nerve via altering the dilation of the ocular vasculature,. [46] 
This could be important in determining the nerve’s response to stress and 
dysfunction could lead to retinal ganglion cell death. eNOS was shown to be 
significantly associated with PACG in our Australian cohort at both the allelic and 
haplotypic level, suggesting that NO regulation plays a pathogenic role in PACG.  
 
NO enhances expression of MMP9. [24] As we have previously reported an 
association of the MMP9 gene with PACG in this Australian cohort [25] we 
evaluated the data at both genes combined and show that patients carrying PACG 
risk alleles at both MMP9 and eNOS have double the risk of developing the disease 
compared to carrying no risk alleles. As the genetic architecture of PACG is 
unravelled, more detailed genetic risk matrices could be developed, which will better 
predict which patients with primary angle-closure suspect are likely to progress to 
PACG and thus require close monitoring. 
  
NTF4 variants were reported to have a minor contribution in the pathogenesis of 
POAG. [47] Variations in NTF4 were not associated with PACG in an Indian 
population. [31] This study reported that the most prevalent variant, A88V, was 
present in controls (4.91%) at a higher frequency than in cases (2.85%) [48] which is 
opposite to the findings in a large cohort of POAG. [14] Neither of our cohorts 
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showed robust association at this locus. Thus NTF4 is unlikely to be a risk locus for 
PACG.  
 
In conclusion, we find no evidence for association of NTF4 or CYP1B1 with PACG 
in either the Australian or Nepalese cohort. SNPs and haplotypes in the eNOS gene 
are associated with PACG in the Australian cohort. The lack of association of this 
gene in the Nepalese may be due to a true negative finding, or insufficient power in 
this cohort to detect an effect and larger cohorts will be required to determine this. 
The NO pathway has long been implicated in glaucoma. The findings here may 
indicate common molecular pathways leading to optic nerve susceptibility to 
glaucoma relevant to both POAG and PACG. 
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Table 1. Characteristics of the Nepalese and Australian cohorts.  
 
Variables Australian Nepalese 
Case Control p-value Case Control p-value 
Number 129 288 - 106 204 - 
Sex  (% female) 62% 53% 0.20 76% 75% 0.85 
Mean age in years (SD) 72(11.7) 69(11.2) 0.01 57.3(12.30) 60.3(13.71) 0.07 
Mean SE in dioptres (SD) 2.2 (2.8) 0.12 (0.37) <0.01 -0.30 (1.64) 0.10 (0.31) 0.16 
IOP in mmHg 24.5 (14) 14.6 (3.4) <0.01 21.3 (17.7) 12.8 (2.3) <0.01 
Cup/disc ratio 0.5 (0.25) 0.2 (0.25) <0.01 0.8 (0.11) 0.2 (0.12) <0.01 
 
SD, standard deviation; SE, spherical equivalent; IOP intra ocular pressure. 
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Table 2 Allele frequencies (%) of the SNPs in Australian Cohort and unadjusted p-value for association under the allelic model with odds ratio (95% 
CI). Values in bold considered significant (p<0.05).  
p*= p-value adjusted for sex and age. OR (95% CI)= odds ratio (95% confidence interval). Chr= chromosome. MAF= minor allele frequency
Gene Chr SNP position SNP Minor Allele MAF p-value OR  (95% CI) p* 
CYP1B1 2 
1 rs2855658 A 0.42 0.289 0.9 (0.7-1.2) 0.337 
2 rs10916 G 0.22 0.821 1.0 (0.7-1.4) 0.762 
3 rs162562 C 0.22 0.821 1.0 (0.7-1.4) 0.762 
4 rs162561 A 0.14 0.343 1.0 (0.7-1.4) 0.437 
5 rs2551188 T 0.30 0.675 0.9 (0.7-1.2) 0.619 
eNOS 7 
1 rs3793342 T 0.08 0.003 0.5 (0.3-0.8) 0.001 
2 rs1799983 T 0.32 0.776 1.1 (0.8-1.4) 0.671 
3 rs3918227 A 0.08 0.745 1.2 (0.7-2.0) 0.743 
4 rs3918186 T 0.06 0.492 0.6 (0.3-1.2) 0.268 
5 rs3918188 A 0.42 0.014 1.5 (1.1-1.9) 0.033 
6 rs1808593 G 0.27 0.186 1.1 (0.8-1.6) 0.164 
7 rs7830 A 0.29 0.007 0.7 (0.5-1.0) 0.003 
NTF4 19 
1 rs12973356 G 0.10 0.185 0.8 (0.5-1.2) 0.119 
2 rs11669977 G 0.36 0.739 0.9 (0.6-1.2) 0.961 
3 rs4802546 T 0.17 0.554 1.1 (0.8-1.7) 0.714 
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Table 3.  Haplotypes of eNOS gene in the Australian population (>1% frequency) and 
its association with PACG.  Bold values are considered significant at the p<0.05 level. 
The order of the SNPs follow table 2 
Haplotype 
1 2 3 4 5 6 7 
Cases Controls OR(95% CI) p-value 
C G C A A T A 0.18 0.19 0.9 (0.6-1.5) 0.844 
T G C T C T A 0.04 0.07 0.5 (0.2-1.2) 0.093 
C G C A A T C 0.25 0.15 1.5 (0.9-2.4) 0.009 
T G C A C T C 0.02 0.05 0.4 (0.1-1.4) 0.083 
C T A A C T C 0.08 0.07 1.1 (0.5-2.3) 0.692 
C G C A C T A 0.10 0.13 0.8 (0.5-1.5) 0.327 
T G C A C T A 0.02 0.05 0.4 (0.1-1.2) 0.055 
C T C A C G C 0.22 0.18 1.4 (0.9-2.3) 0.228 
C G C A C T C 0.09 0.11 0.9 (0.4-1.9) 0.688 
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Table 4. Allele frequencies (%) of the SNPs in Nepalese Cohort and unadjusted p-value for association under the allelic model, with odds ratio (95% 
CI). Values in bold considered significant (p<0.05).  
  
Gene Chr SNP position SNP Minor Allele MAF p-value OR  (95% CI) p* 
CYP1B1 2 1 rs2855658 A 0.19 0.46 1.1 (0.7-1.8) 0.31 
2 rs10916 G 0.09 0.02 2.1 (1.1-4.0) 0.02 
3 rs162562 C 0.13 0.09 1.5 (0.9-2.6) 0.07 
4 rs162561 A 0.1 0.01 2.2 (1.1-4.3) 0.02 
5 rs2551188 T 0.38 0.54 1.1 (0.7-1.5) 0.62 
eNOS 7 1 rs3793342 T 0.1 0.99 1.0 (0.5-1.7) 0.95 
2 rs1799983 T 0.19 0.73 1.0 (0.7-1.6) 0.76 
3 rs3918227 A 0.04 0.17 0.5 (0.2-1.2) 0.22 
4 rs3918186 T 0.11 0.92 1.0 (0.6-1.7) 0.9 
5 rs3918188 A 0.33 0.87 0.9 (0.6-1.3) 0.99 
6 rs1808593 G 0.28 0.42 1.1 (0.8-1.7) 0.46 
7 rs7830 A 0.38 0.39 0.8 (0.6-1.2) 0.41 
NTF4 19 
1 rs12973356 G 0.49 0.67 1.1 (0.7-1.5) 0.77 
2 rs11669977 G 0.22 0.04 1.5 (1.0-2.4) 0.17 
3 rs4802546 T 0.14 0.46 1.1 (0.8-1.5) 0.36 
p*= p-value adjusted for sex and age. OR (95% CI)= odds ratio (95% confidence interval). Chr= chromosome. MAF= minor allele frequency.
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Table 5.  Haplotypes of CYP1B1 and NTF4 genes in the Nepalese population (>1% 
frequency) and its association with PACG.  Bold values are considered significant at the 
p<0.05 level. The order of SNPs follow table 3 
Gene Haplotype 
1  2  3  4  5 
Frequency cases Frequency 
controls 
p-value 
CYP1B1 
 
 
 
 
A  T  C  C  T 0.03 0.04 0.76 
G  T  A  C  T 0.34 0.31 0.53 
A  G  C  A  C 0.10 0.05 0.02 
A  T  A  C  C 0.05 0.08 0.26 
G  T  A  C  C 0.48 0.52 0.24 
NTF4 
 
 
 
C  A  C 0.30 0.33 0.57 
G  G  C 0.22 0.16 0.18 
C  G  T 0.22 0.22 0.94 
C  G  C 0.26 0.29 0.38 
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Figure 1: Gene ideograms depicting the location of tag SNPs genotyped for each candidate gene. Exons are indicated by solid boxes and joined by 
introns indicated by lines. The direction of transcription is indicated by arrows. Translated regions of exons are coloured dark green and untranslated regions 
are light green. “* and †” indicate the tag SNP selected to represent variation in the Australian and Nepalese cohorts, respectively. Unmarked SNPs are 
tagging SNPs in both populations. Figure adapted from NCBI website (http://www.ncbi.nlm.nih.gov/gene). (A) CYP1B1 (B) eNOS (C) NTF4. 
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